Estimating the budget impact of orphan drugs in Sweden and France 2013-2020

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Hutchings, Adam ^a   Schey, Carina ^b   Dutton, Richard ^c   Achana, Felix ^d   Antonov, Karolina ^e  

^a Dolon Ltd   (United Kingdom)

^b GMAS Sàrl ^*  (Switzerland)

^c KeyFormula Ltd   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e LIF   (Sweden)

Author keywords

Budget impact; Europe; Health economics; Orphan medicines

Indexed keywords

ORPHAN DRUG;

ARTICLE; BUDGET; COMPARATIVE STUDY; DRUG COST; DRUG MARKETING; EUROPE; FRANCE; GROWTH RATE; HEALTH CARE SYSTEM; PATENT; PROTECTION; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SWEDEN;

BUDGETS; FRANCE; ORPHAN DRUG PRODUCTION; SWEDEN;

EID: 84896704935     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-22     Document Type: Article

References (30)

1. About rare diseases. EURORDIS, http://www.eurordis.org/about-rare- diseases
2. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF
3. Orphan drug: development trends and strategies. Sharma A, Jacob A, Tandon M, Kumar D, J Pharm Bioallied Sci 2010 2 290 299 10.4103/0975-7406.72128 21180460
4. Community register of medicinal products. European Commission, 2013 http://ec.europa.eu/health/documents/community-register/html/orphreg.htm. Analyzed May 2013
5. Pricing and reimbursement of orphan drugs: the need for more transparency. Simoens S, Orphanet J Rare Dis 2011 6 42 10.1186/1750-1172-6-42 21682893
6. A comparative study of European rare disease and orphan drug markets. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, Health Policy 2010 97 173 179 10.1016/j.healthpol.2010.05.017 20800761
7. Orphan drug pricing may warrant a competition law investigation. Roos JC, Hyry HI, Cox TM, BMJ 2010 341 6471 10.1136/bmj.c6471 21081598
8. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. Sheldon T, BMJ 2012 345 5461 10.1136/bmj.e5461 22890124
9. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, J Med Econ 2010 13 2 295 301 10.3111/13696998.2010.491427 20482245
10. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino J, Soto J, Casado MA, Oyaguez I, Appl Health Econ Health Policy 2010 8 301 315 10.2165/11531880-000000000-00000 20804223
11. Market uptake of orphan drugs-a European analysis. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S, J Clin Pharm Ther 2012 37 664 667 10.1111/j.1365-2710.2012.01364.x 22731105
12. Eurordis survey on orphan drugs availability in Europe. 6th eurordis round table of companies workshop, Barcelona, 9 July 2007. Bignami F, 2007 http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf
13. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Schey C, Milanova T, Hutchings A, Orphanet J Rare Dis 2011 6 62 10.1186/1750-1172-6-62 21951518
14. Inventory of access and prices of orphan drugs across Europe. Le Cam Y, http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC-13122010-YLeCam-Final.pdf
15. Access mechanisms for orphan drugs: a comparative study of selected European countries. Garau M, Mestre-Ferrandiz J, OHE Briefing 2009 52 1 24
16. EMINET. Initial investigation to assess the feasibility of a coordinated system to access orphan medicines. Habl C, Bachner F, Vienna: Commissioned by the European Commission, Directorate-General Enterprise and Industry Updated Final Report. 2011
17. Intercontinental Medical Statistics (IMS) Health database. MIDAS 2013 Data on file
18. Groupement pour l'Elaboration et la Réalisation de Statistiques (GERS). 2013 Data on file
19. Orphan drugs US food and drug administration. 2013 http://www.accessdata. fda.gov/scripts/opdlisting/oopd/OOPD-Results-2.cfm ] Data on file. Analyzed March 2013
20. Developing Products for rare Diseases and Conditions. US Food and Drug Administration, http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/default.htm
21. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Lunn DJ, Thomas A, Best N, Spiegelhalter D, Stat Comput 2000 10 325 337 10.1023/A:1008929526011
22. Patent and marketing exclusivity analysis. 2012 Celgene Data on file
23. 4 Tandvårds- och läkemedelsförmånsverkets föreskrifter och allmänna råd om prissättning av utbytbara läkemedel och utbyte av läkemedel m.m. TLVFS, 2009 http://www.tlv.se/Upload/Lagar-och-foreskrifter/tlvfs-2011-4.pdf
24. Rapport d'activitite 2012. Comite Economique Des Produits De Sante, 2013 http://www.sante.gouv.fr/les-activites-du-ceps.html
25. Tandvårds- och läkemedelsförmånsverket (TLV). http://www.tlv.se/apotek/apotekets-marginaler/%5D
26. Orphanet. Orphan Drugs. The number of orphan medicine designations passes the 1000 milestone in Europ. 2012 http://www.orpha.net/actor/EuropaNews/2012/ 120620.html
27. Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe. EURORDIS, 2009 http://www.eurordis.org/sites/ default/files/publications/Statement-Future-of-Orphan-Drugs-14-October-09.pdf
28. The impact of biosimilars' entryin the EU market. Rovira J, Espín J, García L, Olry de Labry A, 2011 http://ec.europa.eu/enterprise/ sectors/healthcare/files/docs/biosimilars-market-012011-en.pdf
29. European medicines agency. http://www.ema.europa.eu/ema/index.jsp?curl= search.jsp&q=imatinib&btnG=Search&mid=WC0b01ac058001d124
30. European commission. Pharmaceutical sector inquiry. Preliminary report. 2008 http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/ preliminary-report.pdf